Delivery Order SPE2DB22D3009-SPE2DB25FBB90
- Not listed
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a $9,257.14 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL. This non-competitive, competitively awarded contract is structured as a firm fixed price delivery order with a completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its pharmaceutical distribution...
- The Defense Logistics Agency awarded a $13,333.53 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this delivery order fulfills immediate pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $5,857.24 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a biologic medication used to treat inflammatory conditions. This contract, awarded on July 21, 2025, represents a firm fixed-price delivery order with an ultimate completion date of July 22, 2025. The contract carries no set-aside designation and was awarded competitively. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a $5,437.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (adalimumab) pen auto-injectors containing 40 mg/0.4 mL doses. This non-set-aside contract represents a single delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used immunosuppressant medication for treating various autoimmune conditions, and...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBB90Delivery Order
The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to treat various autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime indefinite delivery vehicle provides comprehensive global pharmaceutical support to military healthcare systems, enabling the supply of specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. AmerisourceBergen's role as a pharmaceutical prime vendor reflects its established capability to meet federal medical procurement requirements and support the Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 7/28/25 |